[{"address1": "3201 Carnegie Avenue", "city": "Cleveland", "state": "OH", "zip": "44115-2634", "country": "United States", "phone": "216 431 9900", "fax": "216 361 9495", "website": "https://www.athersys.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.", "fullTimeEmployees": 24, "companyOfficers": [{"maxAge": 1, "name": "Ms. Z. Kasey Rosado", "age": 49, "title": "Interim Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 1508414, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Senthil  Ranganathan Ph.D.", "title": "Vice President of Technical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Russ M.B.A.", "title": "Vice President of Supply Chain, Finance & Administration", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Manal  Morsy M.B.A., M.D., PH.D.", "title": "Executive VP & Head of Global Regulatory Affairs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Mays Ph.D.", "title": "Executive VP, Head of Regenerative Medicine & Neuroscience Programs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rakesh  Ramachandran MS", "title": "Head of Information Technology & Communications and VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Busch Ph.D.", "title": "VP of Regenerative Medicine & Head of Business Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Gurley", "title": "Manager of Corporate Communications and Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 1, "overallRisk": 5, "governanceEpochDate": 1706400000, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.02414, "open": 0.0236, "dayLow": 0.0236, "dayHigh": 0.0291, "regularMarketPreviousClose": 0.02414, "regularMarketOpen": 0.0236, "regularMarketDayLow": 0.0236, "regularMarketDayHigh": 0.0291, "beta": -0.901, "volume": 2240540, "regularMarketVolume": 2240540, "averageVolume": 2660561, "averageVolume10days": 3516031, "averageDailyVolume10Day": 3516031, "marketCap": 1666407, "fiftyTwoWeekLow": 0.0045, "fiftyTwoWeekHigh": 0.0425, "priceToSalesTrailing12Months": 20.830088, "fiftyDayAverage": 0.019348947, "twoHundredDayAverage": 0.019348947, "currency": "USD", "enterpriseValue": 19223408, "floatShares": 61154088, "sharesOutstanding": 61718800, "sharesShort": 993200, "sharesShortPriorMonth": 795503, "sharesShortPreviousMonthDate": 1693440000, "dateShortInterest": 1695945600, "sharesPercentSharesOut": 0.0372, "heldPercentInsiders": 0.0077, "heldPercentInstitutions": 0.03059, "shortRatio": 3.32, "shortPercentOfFloat": 0.0378, "impliedSharesOutstanding": 61718800, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -37507000, "enterpriseToRevenue": 240.293, "enterpriseToEbitda": -0.681, "52WeekChange": 0.33663368, "SandP52WeekChange": 0.20883334, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ATHXQ", "underlyingSymbol": "ATHXQ", "shortName": "Athersys, Inc.", "longName": "Athersys, Inc.", "firstTradeDateEpochUtc": 1704205800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "32e8db8c-abb2-33fe-9b59-c7881f90dde1", "messageBoardId": "finmb_25192", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.027, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 1020000, "totalCashPerShare": 0.017, "ebitda": -28217000, "totalDebt": 18577000, "quickRatio": 0.026, "currentRatio": 0.058, "totalRevenue": 80000, "revenuePerShare": 0.004, "returnOnAssets": -0.83565, "freeCashflow": -25451000, "operatingCashflow": -26358000, "operatingMargins": -359.0875, "financialCurrency": "USD", "trailingPegRatio": null}]